TACR2

Substance-K receptor · P21452 · TACR2 on Sugi Atlas →

121,633 patent compounds predicted against TACR2, 75,714 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Osanetant (SCHEMBL119440)	1.00	17/20
SCHEMBL186638	0.57	15/20
Saredutant (SCHEMBL185911)	1.00	14/20
Segetalin B (SCHEMBL151686)	0.51	11/20
Talnetant (SCHEMBL74220)	1.00	6/20
Talnetant (SCHEMBL74221)	1.00	6/20
Segetalin A (SCHEMBL151176)	0.64	4/20
Oxiconazole (SCHEMBL34518)	1.00	3/20
Oxiconazole (SCHEMBL34519)	1.00	3/20
Sulconazole (SCHEMBL34761)	1.00	3/20
Sulconazole (SCHEMBL34762)	1.00	3/20
Nolpitantium (SCHEMBL157084)	0.56	3/20
Hydrochloric Acid (SCHEMBL159575)	0.53	3/20
SCHEMBL43309	0.43	3/20
SCHEMBL108493	0.41	3/20
Miconazole (SCHEMBL2866)	1.00	2/20
(R)-Miconazole (SCHEMBL2867)	1.00	2/20
Lovastatin (SCHEMBL3136)	1.00	2/20
Lovastatin (SCHEMBL3137)	1.00	2/20
Paclitaxel (SCHEMBL3976)	1.00	2/20

Clinical trials — most relevant to TACR2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 3	PHASE4	COMPLETED
Blood Pressure Regulation - Role of Potassium	PHASE4	COMPLETED
Effects of Genotype on Resting State Connectivity During Methamphetamine Administration	PHASE4	COMPLETED
The Role of Angiotensin Type I Receptor in the Regulation of Human Coronary Vascular Function	PHASE3	COMPLETED
Intravitreal Triamcinolone Acetonide Versus Laser for Diabetic Macular Edema	PHASE3	COMPLETED
The Effect of NK1R Antagonism on Alcohol Craving and PTSD Symptoms in Alcohol Dependent Patients With PTSD	PHASE2	COMPLETED
A Series of Pilot Studies to Evaluate the haemoDynamic and mEtabolic Effects oF apelIn aNd rElaxin	PHASE2	UNKNOWN
Tacrine Effects on Cocaine Self-Administration and Pharmacokinetics	PHASE2	WITHDRAWN
Psychopharmacology for Cocaine Dependence - Buspirone	PHASE2	COMPLETED
Effect of LY686017 on Alcohol Craving	PHASE2	COMPLETED
Efficacy and Safety of Azilsartan in Subjects With Essential Hypertension	PHASE2	COMPLETED
Calcium Channel Blockade in Primary Aldosteronism	PHASE2	COMPLETED
Proof-of-Concept Trial to Assess the Efficacy and Safety of Fezolinetant in Improving Vasomotor Symptoms in Men With Prostate Cancer Undergoing Androgen Deprivation Therapy	PHASE2	RECRUITING
Evaluation of Substance P Neurotransmission in Panic Disorder by PET Imaging of NK1 Receptors With [18F]SPA-RQ	PHASE1	COMPLETED
Brain Networks and Addiction Susceptibility	PHASE1	COMPLETED
The Role of microRNAs in Organ Remodeling in Lower Urinary Tract Dysfunction	nan	COMPLETED
Changes in Inflammatory and Contractile Protein Expression in Patients With Painful Bladder Syndrome/IC.	nan	COMPLETED
Precision Medicine for Nociception, Sngception and Proprioception.	nan	RECRUITING
Role of Substance P in Post-Traumatic Stress Disorder	nan	COMPLETED
Local, Targeted Therapy With Alpha Emitter [225Ac]Ac-DOTA-SP (TAT) in Glioma (WHO G3-G4) Progression	nan	RECRUITING
Study to Evaluate if the Drug Vasopressin Protects the Kidneys for Patients Undergoing Liver Transplant	nan	COMPLETED
Pharmacogenetics of Alcohol: Treatment Implications	nan	COMPLETED
Pharmacogenetic and Neurofunctional Brain Areas Study in Obese Patients With Binge Eating Disorder	nan	UNKNOWN
A Study of the Impact of Genetic Testing on Clinical Decision Making and Patient Care	nan	UNKNOWN
GABRA2 and the Pharmacokinetics of Risk for Alcoholism (GPRA)	nan	COMPLETED
Renal Transporters After Renal Transplantation	nan	UNKNOWN
Affective Touch, Hedonia and Suicidal Behavior	nan	COMPLETED
Relationship of Brain Natriuretic Peptide (BNP) Levels to Cardiac Diagnosis, Operation Performed, Post-operative Course and Outcome	nan	COMPLETED
The Genetic Basis for Vulnerability to Substance Abuse	nan	COMPLETED
Efficacy and Safety of Angiotensin II Use in Coronavirus Disease(COVID)-19 Patients With Acute Respiratory Distress Syndrome	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a TACR2 binder may also engage these)

Protein	Name	Similarity
Q5DUB2	—	1.000	Q5DUB2 →
Q64077	—	1.000	Q64077 →
P16610	—	1.000	P16610 →
P05363	—	0.999	P05363 →
P51144	—	0.997	P51144 →
P30549	—	0.995	P30549 →
P79218	—	0.995	P79218 →
P56718	—	0.959	P56718 →
O97661	—	0.958	O97661 →
HCRTR1	Orexin/Hypocretin receptor type 1	0.957	landscape →
P30098	—	0.956	P30098 →
Q9EP86	—	0.955	Q9EP86 →
Q9WTV9	—	0.953	Q9WTV9 →
O42329	—	0.953	O42329 →
Q9WUK7	—	0.952	Q9WUK7 →
P97295	—	0.952	P97295 →
P58307	—	0.952	P58307 →
Q9WTV8	—	0.951	Q9WTV8 →
O62809	—	0.951	O62809 →
P30975	—	0.950	P30975 →
Q9H1Y3	—	0.949	Q9H1Y3 →
Q0GBZ5	—	0.949	Q0GBZ5 →
OXTR	Oxytocin receptor	0.949	landscape →
P70536	—	0.949	P70536 →
P56449	—	0.949	P56449 →
Q90252	—	0.949	Q90252 →
NPFFR1	Neuropeptide FF receptor 1	0.949	landscape →
P56494	—	0.948	P56494 →
P32306	—	0.948	P32306 →
Q9Z2D5	—	0.947	Q9Z2D5 →